Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Natco Pharma Ltd. Share Price
Day's Range
Day's Range
Low
₹1,140.20
High
₹1,162.40
Price Summary
| Previous Close | ₹1,158.00 |
|---|---|
| Day's Range | ₹1,140.20 - ₹1,162.40 |
| Open | ₹1,155.00 |
| 52 Week Range | ₹775.00 - ₹1,218.00 |
| Volume | 44,525 |
| Market Cap | ₹0.02 |
| Previous Close | ₹1,164.65 |
|---|---|
| Day's Range | ₹1,140.90 - ₹1,175.95 |
| Open | ₹1,175.95 |
| 52 Week Range | ₹752.10 - ₹1,217.40 |
| Volume | 4,657 |
| Market Cap | ₹0.02 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 515.60 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.51 |
| Price/Earning (TTM) | 13.50 |
| TTM EPS (₹) | 86.94 |
| P/E Ratio | 7.57 |
| Book Value(₹) | 2.39 |
| PAT Margin (%) | 39.54 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 32.85 |
| Trade Value ( ₹ in Lacs) | 54.24 |
|---|---|
| Market Cap (₹ in Mn) | 0.02 |
| Dividend Yield(%) | 0.51 |
| Price/Earning (TTM) | 13.50 |
| TTM EPS (₹) | 86.94 |
| P/E Ratio | 7.57 |
| Book Value(₹) | 2.39 |
| PAT Margin (%) | 39.54 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 32.85 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 4076.0 | 35689.0 |
| Expenses | N/A | N/A |
| PBT | 1503.0 | 15553.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 1249.0 | 13066.0 |
About Natco Pharma Ltd.
| Founded | 1981 |
|---|---|
| Managing Director | V C Nannapaneni |
| NSE Symbol | NATCOPHARM |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,43,229.15 | 1,848.30 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,78,100.22 | 6,690.50 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,48,250.95 | 4,434.80 | 3,101.60 - 3,101.60 |
| Apollo Hospitals Enterprise Ltd. | 1,16,391.52 | 8,111.00 | 6,677.50 - 6,677.50 |
| Cipla Ltd. | 1,08,864.87 | 1,342.20 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,08,721.36 | 2,296.25 | 1,836.80 - 1,836.80 |
| Dr. Reddy's Laboratories Ltd. | 1,07,942.01 | 1,281.00 | 1,138.50 - 1,138.50 |
| Mankind Pharma Ltd. | 1,00,199.63 | 2,423.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 98,526.33 | 1,025.70 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 94,475.31 | 937.00 | 835.50 - 835.50 |
No Records Found
Latest News
NATCO Pharma informs about press release
NATCO Pharma informs about analyst meet
Pursunt to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, NATCO Pharma has informed that the officials of the Company will be participating in Investec Promoter and Founder Conference 2026 on 9th March 2026 at 9:00 am to 5:00 pm. No Unpublished Price Sensitive Information (UPSI) is intended to be discussed during the interactions.
The above information is a part of company’s filings submitted to BSE.
Natco Pharma informs about clarification on volume movement of shares
NATCO Pharma informs about press release
Natco Pharma informs about un-audited financial results
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Natco Pharma Ltd. is ₹1,158.00 as of 2026-05-11.
The market capitalisation of Natco Pharma Ltd. is ₹21,027.50 as of 2026-05-08.
The 1-year return of Natco Pharma Ltd. is -16.70% as of 2026-05-11.
The P/E ratio of Natco Pharma Ltd. is 7.57 as of 2026-05-11.
The 52-week high and low of Natco Pharma Ltd. are ₹1,218.00 and ₹775.00, respectively, as of 2026-05-11.
People Also Ask
Natco develops generic and specialty drugs, with strong positions in oncology, cardiology, gastro, and CNS, plus agro‑chemicals through its crop‑health division.
Natco collaborates on licensing, contract manufacturing, and supplies hospital‑focused oncology generics and complex formulations in India and export markets.
Disclaimer
This content is for educational purpose only and the same should not be construed as investment advice. Bajaj Finserv Direct Limited shall not be liable or responsible for any investment decision that you may take based on this content.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
